Last reviewed · How we verify
Ibuprofen EchoG
Ibuprofen EchoG is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation.
Ibuprofen EchoG is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation. Used for Pain and inflammation (specific Phase 3 indication unclear from available data).
At a glance
| Generic name | Ibuprofen EchoG |
|---|---|
| Also known as | Echocardiographically guided ibuprofen treatment |
| Sponsor | Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX-1, COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain management, Inflammation |
| Phase | Phase 3 |
Mechanism of action
Like conventional ibuprofen, this formulation blocks COX-1 and COX-2 enzymes, thereby decreasing production of pro-inflammatory prostaglandins and providing analgesic, anti-inflammatory, and antipyretic effects. The 'EchoG' designation likely refers to a specific formulation, delivery mechanism, or imaging-related variant under investigation by the Spanish research foundation, though the core mechanism remains NSAID-based inhibition of prostaglandin synthesis.
Approved indications
- Pain and inflammation (specific Phase 3 indication unclear from available data)
Common side effects
- Gastrointestinal upset
- Dyspepsia
- Abdominal pain
- Nausea
- Headache
Key clinical trials
- Clinical Trial to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis (PHASE3)
- Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: